Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07409181 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 405
- Enrollment target
NCT07409181 is a Phase 2 study that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 405 participants.
The verdict
NCT07409181, a Phase 2 study, is actively recruiting participants, sponsored by Boehringer Ingelheim.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 405 participants
- Enrollment target
Study Summary
This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE. The study tests different doses of BI 3000202 and aims to find the best dose for people with this condition. Participants are put into 5 groups randomly, which means by chance. 4 groups get different doses of BI 3000202, and 1 group gets a placebo. Placebo tablets look like BI 3000202 tablets but do not contain any medicine. Participants take the tablets for 1 year. All participants also continue their regular treatment for SLE. Participants are in the study for a bit longer than 1 year. During this time, they visit the study site regularly. Doctors check the participants' health and take note of any unwanted effects. They also compare the results between the groups to see if the treatment works.
Interventions
- DRUG Placebo
- DRUG BI 3000202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2026-04-20 |
| Est. Completion | 2029-07-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07409181
The ClinicalTrials.gov registry entry for NCT07409181 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 405 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07409181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07409181 about?
NCT07409181 is a clinical study titled "A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)". This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE. The study tests different doses of BI 3000202 and aims to find the best dose for people with this condition. Participants are pu...
What is the current status of trial NCT07409181?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 405 participants. The study started on 2026-04-20. Estimated completion is 2029-07-08.
What interventions are being tested in trial NCT07409181?
The interventions under investigation include: Placebo (DRUG), BI 3000202 (DRUG).
Who is sponsoring clinical trial NCT07409181?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.